HOSPIRA will initiate a voluntary
nationwide recall to the user
level for one lot of labetalol
hydrochloride injection, USP,
100 mg/20 mL (5 mg/mL) 20 mL
multidose vial.
The recall is due to embedded
particulate within the glass vial
and visible particles floating in the
solution; the embedded particulate
was identified as stainless steel and
the visible particles as iron oxide.
There is no evidence of this fault
affecting Australian supplies.
For more, CLICK HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 23 May 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 May 14
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.